Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471570 | 0.95 | KIF11 (0.43) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL12582832 | 0.94 | KIF11 (0.42) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL8327519 | 0.94 | KIF11 (0.42) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL14277882 | 0.92 | SLC6A11 (0.41) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL16021678 | 0.90 | KIF11 (0.46) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL18413416 | 0.85 | KIF11 (0.47) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL5819858 | 0.85 | KIF11 (0.47) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL5819943 | 0.85 | KIF11 (0.47) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL13425184 | 0.85 | KIF11 (0.40) | KIF11KCNH2SLC6A1SLC6A11TK2 | |
| SCHEMBL12582837 | 0.84 | SLC6A11 (0.41) | KIF11SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507455-B2 | Folate conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20090247614-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247614-A1 | Folate Conjugates | FOLR2, FOLR1, NSUN2 | KIF11 3300/4885KCNH2 3039/4885SLC6A1 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.